Clinical Trial Detail

NCT ID NCT03498716
Title A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel

Cyclophosphamide + Epirubicin + Paclitaxel

Age Groups: senior adult

No variant requirements are available.